Modifiedblue cross blue shield - louisianaPolicy AHS - G2022 - Biomarker Testing for Autoimmune Rheumatic Disease

Biomarker Testing for Autoimmune Rheumatic Disease

Coverage rules for laboratory biomarker testing (ANA, ENA, RF, anti-CCP, dsDNA, and related panels) used in diagnosis and monitoring of systemic autoimmune rheumatic diseases for Blue Cross and Blue Shield of Louisiana members.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyBiomarker Testing for Autoimmune Rheumatic Disease

Policy CodePolicy AHS - G2022 - Biomarker Testing for Autoimmune Rheumatic Disease

Change TypeComprehensive review with coverage clarifications and coding updates

Effective Date09/01/2025

Next Review Date

Key ActionDocument clinical signs or symptoms to justify initial or repeat ANA, RF, or anti-CCP testing consistent with allowed frequencies.

SourceLink

POLICY UPDATE CHANGES

CC1, CC2, and CC3 edited for clarity on allowed frequency of biomarker testing and now specify initial testing frequency and allowance for up to two additional lifetime tests in defined circumstances.

New CC10 added: testing for serum biomarkers not discussed above, alone or in a panel (e.g., Seronegative Rheumatoid Arthritis Profile), DOES NOT MEET COVERAGE CRITERIA.

Former CC12 expanded to include additional proprietary tests (aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile) and renumbered as CC13, and proprietary algorithm/index panel testing for SLE/CTD stated DOES NOT MEET COVERAGE CRITERIA.

Off-cycle coding modification: Added CPT code 0521U and removed CPT code 0456U on 01/01/2025.

09/01/2025 review updated background, guidelines, evidence-based references and edited CCs for clarity including allowed frequency of biomarker testing.

OnceANA testing allowed during initial workup

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Biomarker Testing

Covered testing

Covered when specified clinical conditions are met:

ANA screening: For individuals with signs or symptoms of an autoimmune disease, screening for disease using antinuclear antibodies (ANA) meets coverage criteria.Once during initial workup; up to two additional tests per lifetime if new or more severe signs or symptoms develop

Clinical signs/symptoms required; see documentation guidance.

ENA panel after abnormal ANA: For individuals with an abnormal, raised ANA titer and a clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigens (ENA) panel testing of specific autoantibodies meets coverage criteria.

Reflex testing following abnormal ANA and clinical correlation.

RF and anti-CCP for suspected RA: For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies meets coverage criteria.Once during initial workup; if initial testing did not result in a diagnosis, up to two additional tests per lifetime if symptoms persist or additional symptoms develop

Intended for patients with synovitis/high pretest probability.

dsDNA testing in diagnosed SARD: For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, testing of dsDNA up to four (4) times per year meets coverage criteria.Up to 4 times per year

Used for monitoring when clinically indicated in diagnosed patients.

Condition-specific antibody testing with negative/low ANA: For individuals with a negative or low positive ANA test, specified condition‑specific antibody testing meets criteria in defined clinical scenarios (examples: anti‑Jo‑1 for a myositis subset; anti‑SSA for suspected lupus or Sjögren's).

Limited to the clinical scenarios listed.

Reflex testing after positive ANA

Reflex testing and follow-up after ANA screening:

ANA-positive follow-up: If an ANA screen is positive and clinical suspicion for a systemic autoimmune rheumatic disease (SARD) exists, perform anti-dsDNA testing and identify ENA sub-specificities; consider reflex testing guided by IIF pattern and titer.Consider reflexes for ANA titre >1:160 for certain patterns

Pattern-specific reflex recommendations (see Table 1): e.g., homogeneous → anti-dsDNA and ENA; centromere high titre may not require confirmation; anti-CENP‑B reserved for low/ambiguous centromeric patterns.

Assay selection

Selection of initial ANA/autoantibody assay:

Assay selection considerations: Indirect immunofluorescence (IIF) on HEp‑2 substrate remains the gold standard for ANA testing because of sensitivity and pattern recognition; solid‑phase assays (ELISA, CIA, FEIA, MIA) offer higher throughput and differing sensitivity/specificity and may be used, but if clinical suspicion for SARD is high and a solid‑phase assay is negative, perform IIF.

Laboratories using alternative platforms should provide data on comparative sensitivity to IF ANA on request (ACR position).

Proprietary MAP/CB-CAP testing

Use of MAP/CB‑CAP and other proprietary tests for diagnosis and prognosis:

MAP/AVISE use: Multianalyte panels incorporating cell‑bound complement activation products (CB‑CAPs) (e.g., AVISE Lupus/MAP) have been reported to increase diagnostic specificity and to be associated with higher rates of subsequent SLE diagnosis and clinician treatment changes in some studies.Two‑tiered positive MAP scores were associated with higher likelihood of SLE diagnosis in reported cohorts

Evidence includes randomized and longitudinal studies showing association with diagnosis, treatment changes, and modeled cost impact; proprietary panels remain subject to policy exclusions for certain indications (see Covered and Not Covered Criteria).

Predictive RA testing (PrismRA)

Predictive testing for RA therapeutic response:

PrismRA utility: PrismRA (MSRC) is a 23‑feature molecular signature response classifier that predicts TNF‑inhibitor (TNFi) non‑response prior to treatment initiation and demonstrated clinical validation in CERTAIN and NETWORK‑004 cohorts.High MSRC score indicates decreased likelihood of TNFi response

CERTAIN reported PPV 89.7%, specificity 86.8%, sensitivity 50%; NETWORK‑004 showed OR=4.1 for inadequate TNFi response (ACR50 at 6 months); modeled analyses suggest potential reductions in ineffective treatment costs.

Evidence and Guideline Context

Relevant clinical performance and guideline context for coverage consideration:

PrismRA evidence summary: PrismRA (MSRC) was clinically validated in the CERTAIN prospective study and in NETWORK‑004 with reported PPV 89.7%, specificity 86.8%, sensitivity 50%; NETWORK‑004 reported OR=4.1 for ACR50 at 6 months and modeling suggests improved ACR50 rates and cost reductions when used to stratify therapy.

Supports potential utility for predicting TNFi non‑response; payers may request supporting evidence when considering coverage.

MBDA/Vectra DA context: Vectra DA (MBDA) combines 12 serum biomarkers into a score (≤29 low, 29–44 moderate, >44 high) that correlates with DAS28‑CRP (r≈0.72) and has prognostic associations for radiographic progression, but clinical responsiveness and utility for management are mixed across studies.

Guideline bodies note MBDA may complement clinical assessment but do not universally endorse routine use for management decisions.

Guideline positions affecting coverage: ACR supports HEp‑2 IIF as the gold standard for ANA testing and recommends against ordering ANA subserologies without a positive ANA and clinical suspicion; ACR RA guidelines do not include routine multi‑biomarker tests (e.g., Vectra DA, PrismRA) for diagnostic or disease‑management indications; EULAR/ACR SLE classification uses ANA ≥1:80 on HEp‑2 as an entry criterion.

Covered and Not Covered Criteria (selected summaries)

Covered when specified clinical conditions and frequency limits are met per CCs summarized in revision history:

CC1 - ANA testing: For individuals with signs or symptoms of an autoimmune disease, screening for antinuclear antibodies (ANA) MEETS COVERAGE CRITERIA: a) Once during initial workup. b) Up to two additional tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.lifetime repeats <= 2

From 09/01/2025 revision summary.

CC2 - ENA panel testing: For individuals with an abnormal, raised ANA titer and a clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigens (ENA) panel testing of specific autoantibodies MEETS COVERAGE CRITERIA.standard clinical correlation required

From 09/01/2025 revision summary.

CC3 - RF and anti-CCP testing: For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti‑cyclic citrullinated peptide (anti‑CCP) antibodies MEETS COVERAGE CRITERIA: a) Once during initial workup. b) If initial testing did not result in a diagnosis of RA, up to two additional tests per lifetime if symptoms persist or additional symptoms of RA develop.

Monitoring of disease using serial ANA titers is specifically excluded from coverage. The policy states that monitoring of disease with ANA testing or ANA titers DOES NOT MEET COVERAGE CRITERIA, and that ANA and/or ENA testing in individuals without symptoms suggestive of an autoimmune disorder DOES NOT MEET COVERAGE CRITERIA. Clinical signs or symptoms are required to justify initial ANA/ENA testing; absent those findings, testing may be denied.

Centromere staining patterns reported at high titers generally do not require additional confirmatory testing. Per the ANA-reflex table, no confirmation is necessary if centromere titres are high, and a specific anti-CENP-B assay should be executed only in dubious cases such as low-titre or unclear centromeric patterns.

Consistent with ACR and Choosing Wisely recommendations, the policy discourages ordering ANA subserologies (ENA or other specific autoantibodies) in the absence of a positive ANA and clinical suspicion of immune-mediated disease. The guidance states: Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion of immune-mediated disease.

When this policy conflicts with an applicable government policy (for example, Medicare LCDs/NCDs or state Medicaid rules), the government policy takes precedence. The document disclaims that the government policy will be used to make the determination in such conflicts and directs providers to the relevant government coverage resources.

The policy identifies multiple proprietary serum biomarker panel tests and indexed algorithm scores (examples named include Vectra DA, PrismRA, AVISE CTD/Avise Lupus, aisle® DX, Early Sjögren's Syndrome Profile) and indicates these assays are considered distinct commercial multianalyte panels with algorithmic/index outputs that have been evaluated in the literature but are subject to coverage restrictions in this policy.

Serum biomarker panel testing that uses proprietary algorithms and/or reports an indexed score (for example, Vectra DA, PrismRA, AVISE panels, aisle® DX) is designated as not meeting coverage criteria for the indicated uses. The policy explicitly states that these proprietary algorithm/index panel tests DO NOT MEET COVERAGE CRITERIA for diagnosis, prognosis, or monitoring of SLE/CTD and, where listed, for RA management.

Routine repeat ANA testing after an initially negative ANA within a short interval is discouraged because of low yield and high cost. The policy cites evidence that repeat ANA testing after a negative result has low utility (for example, few conversions and no change in diagnosis when repeated within two years) and indicates repeat testing without new clinical indications may be considered not medically necessary.

Multibiomarker disease activity (MBDA) scores such as Vectra DA have shown mixed performance in the literature; at least one study reported that MBDA scores were not sufficiently responsive for assessing RA disease activity. The policy notes these responsiveness concerns and that MBDA tests are not endorsed as preferred disease activity measures in some analyses.

For management of rheumatoid arthritis and for diagnosis, prognosis, or monitoring of systemic lupus erythematosus and connective tissue diseases, the policy states that specified serum biomarker panels and panels with proprietary algorithm/index scores (examples: Vectra DA, PrismRA, AVISE CTD/Avise Lupus, aisle® DX, Early Sjögren's Syndrome Profile) DO NOT MEET COVERAGE CRITERIA. These panels are therefore considered not medically necessary for those stated indications.

Procedure and CPT/HCPCS Codes

Applicable CPT/HCPCS Procedure Codes (selected)mixed

81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score; Proprietary test: Vectra®DA; Lab/Manufacturer: Crescendo Bioscience, Inc.
86038	Antinuclear antibodies (ANA).
86039	Antinuclear antibodies (ANA); titer.
86200	Cyclic citrullinated peptide (CCP), antibody.
86225	Deoxyribonucleic acid (DNA) antibody; native or double stranded.
86235	Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody.
86430	Rheumatoid factor; qualitative.
86431	Rheumatoid factor; quantitative.
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity; Proprietary test: Anti-dsDNA, High Salt/Avidity; Lab/Manufacturer: University of Washington, Department of Laboratory Medicine/Bio- Rad.
0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score; Proprietary test: SLE-key® Rule Out; Lab/Manufacturer: Veracis Inc.

1–10 of 11

1/2

Additional CPT/HCPCS Procedure Codesmixed

0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare; Proprietary test: aisle® DX Disease Activity Index; Lab/Manufacturer: Progenotes Diagnostics, Inc.
0521U	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood; Proprietary test: Seronegative Rheumatoid Arthritis Panel; Lab Manufacturer: KSL Diagnostics-Beutner Laboratories, Inc, KSL Biomedical, Inc.

Policy-related CPT coding changesCPT

0521U	CPT code added 01/01/2025
0456U	CPT code removed 01/01/2025 (previously added 07/01/2024)
0446U	CPT code added 04/01/2024
0447U	CPT code added 04/01/2024
81490	CPT code added 09/01/2023
0312U	CPT code added 01/01/2023
86200	CPT code added (date noted in history)
86430	CPT code added (date noted in history)
86431	CPT code added (date noted in history)

Provider Requirements, Documentation, and Billing Guidance

Prior Authorization

Proprietary multianalyte testing may require justification

Certain proprietary multianalyte or algorithmic biomarker panels (for example, AVISE® assays, PrismRA, Vectra® DA, aisle® DX, Seronegative Rheumatoid Arthritis Panel, and similar index/algorithm‑based tests) may require additional clinical justification at time of prior authorization or claim review. Justification should explain why standard covered testing (ANA, ENA, RF, anti‑CCP, dsDNA, and targeted condition‑specific autoantibodies) is insufficient for the diagnostic or management question, and provide relevant clinical details (signs/symptoms, prior test results, treatment history, and intended clinical action based on the proprietary test result).

Proprietary tests may be reviewed as experimental/not medically necessary unless documentation demonstrates a clear, incremental clinical utility beyond standard serologies and guideline‑recommended testing.
When submitting a PA request for a proprietary assay, include: clinical indication, prior relevant serologies (ANA, RF, anti‑CCP, dsDNA, ENA results), duration and severity of symptoms, prior treatments (including DMARD/TNFi exposure when relevant), and how the result will change management.

Background and Rationale

Systemic autoimmune rheumatic diseases (SARDs) are heterogeneous disorders characterized by autoantibodies and immune dysregulation affecting multiple organ systems. The policy emphasizes that ANA is used as a screening test with high sensitivity for conditions such as SLE but limited specificity, and that ENA, anti-dsDNA, RF, and anti-CCP provide additional diagnostic specificity in appropriate clinical contexts. Policy coverage determinations are tied to clinical presentation and established guideline criteria (for example, EULAR/ACR SLE classification entry criteria).

Definitions and Test Descriptions

inv-41: ANA — Antinuclear antibody

DefinitionAntinuclear antibody (ANA): a test to detect autoantibodies against intracellular antigens; common screening test for systemic autoimmunity.

Clinical roleUsed as an initial screening test for suspected systemic autoimmune rheumatic disease (SARD); >95% of individuals with SLE have a positive ANA.

Preferred methodHEp-2 indirect immunofluorescence (IIF) is recommended by ACR as the gold standard for ANA testing.

Entry criterion for SLE classificationANA at titer ≥1:80 on HEp-2 cells is an entry criterion for EULAR/ACR SLE classification.

inv-42: ENA — Extractable nuclear antigens

DefinitionExtractable nuclear antigens (ENA): a group of autoantibodies (eg, Sm, RNP, Ro/SS-A, La/SS-B) used to evaluate suspected connective tissue disease.

Policy Revision History

2025-09-01comprehensive_reviewLatest

Reviewed and updated background, guidelines, and evidence; edited CC1-CC3 to clarify allowed frequency of biomarker testing and added CC10 and expanded/renumbered proprietary panel exclusions into CC13.

2025-01-01coding_update

Off-cycle coding modification: added CPT code 0521U and removed CPT code 0456U.

2024-11-15review_update

Reviewed and updated background, guidelines, and evidence-based references; literature review prompted changes in coverage criteria (summary entry).

Policy Summary

Payerblue cross blue shield - louisiana

PolicyBiomarker Testing for Autoimmune Rheumatic Disease

Policy CodePolicy AHS - G2022 - Biomarker Testing for Autoimmune Rheumatic Disease

Change TypeComprehensive review with coverage clarifications and coding updates

Effective Date09/01/2025

Next Review Date

Key ActionDocument clinical signs or symptoms to justify initial or repeat ANA, RF, or anti-CCP testing consistent with allowed frequencies.

SourceLink

On This Page

Billing Rule

Listed procedure codes (verify PA as required)

The following CPT / HCPCS / PLA codes are referenced for these tests and may require prior authorization or may be subject to denial if coverage criteria are not met. Procedure codes cited in this policy are for reference and may not be exhaustive.

81490 — Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers (Vectra® DA)
86038 — Antinuclear antibodies (ANA)
86039 — Antinuclear antibodies (ANA); titer
86200 — Cyclic citrullinated peptide (CCP), antibody
86225 — Deoxyribonucleic acid (DNA) antibody; native or double stranded
86235 — Extractable nuclear antigen, antibody to, any method, each antibody
86430 — Rheumatoid factor; qualitative
86431 — Rheumatoid factor; quantitative
0039U — Anti‑dsDNA, high avidity (U of Washington/Bio‑Rad)
0062U — SLE‑key® Rule Out (Veracis Inc)
0312U — Avise® Lupus (Exagen Inc)
0447U, 0446U — aisle® DX related analyte codes
0521U — Seronegative Rheumatoid Arthritis Panel (KSL Diagnostics)

Billing Rule

Coding update and claim submission

Coding updates and claim submission notes: procedure code additions and off‑cycle coding changes have been made over policy revisions. Providers should confirm current applicable codes and submit the code(s) that best describe the performed assay and report. If multiple CPT/HCPCS codes could apply, include the laboratory report and test name to aid adjudication.

Recent additions in revision history: 86200, 86430, 86431; off‑cycle additions included 0456U, 0446U, 0447U, and 81490 in prior updates.
Submit the laboratory report with claims or prior authorization requests when ordering proprietary or multianalyte tests to avoid denials for insufficient information.

Denial Risk

Coverage denials for inappropriate or unsupported testing

Tests or test uses that do not meet coverage criteria may be denied. Common denial risks include ordering ANA/ENA testing in asymptomatic individuals, repeating ANA after a confirmed negative without new/worsening symptoms, ordering ANA subserologies without a positive ANA and clinical suspicion, and ordering proprietary index/panel tests for routine diagnosis, monitoring, or management without documented justification.

ANA and/or ENA testing for asymptomatic individuals or during routine wellness visits — DENIAL RISK.
Repeat ANA testing after an initial negative result within two years without new or worsening symptoms — DENIAL RISK.
Ordering ANA subserologies (ENA antibodies) without a positive ANA and clinical suspicion — DENIAL RISK.
Proprietary serum biomarker panels/index tests (e.g., Vectra® DA, PrismRA, AVISE® assays, aisle® DX) for diagnosis, prognosis, or routine monitoring when coverage criteria are not met — DENIAL RISK.

Documentation Required

ANA subserologies without positive ANA discouraged

Ordering of ANA sub‑serologies (eg, ENA components) should generally follow a positive ANA result and clinical suspicion for immune‑mediated disease. The American College of Rheumatology and Choosing Wisely guidance discourage ordering ANA subserologies in the absence of a positive ANA and compatible clinical findings.

Do not order ANA subserologies (eg, anti‑Sm, anti‑RNP, anti‑Ro/SSA, anti‑La/SSB) without a positive ANA and documented clinical suspicion of autoimmune disease.
If an ANA is positive, document the titer and clinical correlation that supports reflex or targeted subserology testing.

Documentation Required

Lab method reporting for ANA

Laboratories should specify the method used for ANA detection when reporting results and be able to provide comparative performance data on request. The ACR supports immunofluorescence (HEp‑2 substrate) as the gold standard and advises that alternative platforms provide sensitivity data if requested by the ordering provider.

Report the assay method (eg, IF‑HEp2, multiplex bead, EIA/MIA) on laboratory reports.
Laboratories using alternative bead‑based or solid‑phase assays must provide evidence on request that the alternative assay has equal or improved sensitivity compared with IF ANA.
In-house ANA and related autoantibody assays should be standardized to national/international standards where applicable.

Documentation Required

Clinical documentation to support testing/referral

Submit clinical documentation that supports the requested test or referral. Documentation should clearly state presenting signs and symptoms, duration and severity, prior relevant laboratory results, and how the test result will alter diagnosis or management.

Include presenting signs/symptoms (eg, pattern of joint involvement, photosensitivity, unexplained cytopenias, mucocutaneous findings) and duration of symptoms.
Provide prior serology results (ANA, RF, anti‑CCP, dsDNA, ENA) and imaging or specialist evaluations if available.
For RA‑related tests, document synovitis findings, number of joints involved, and baseline acute phase reactants (ESR/CRP) where relevant.

Documentation Required

Clinical justification for testing

Clinical justification for testing must align with policy coverage criteria: initial workup testing for symptomatic individuals, limited repeat testing when symptoms change, and targeted antibody assays when there is an abnormal ANA with clinical correlation. Routine monitoring with ANA titers or broad panel testing in the absence of clinical indication is not covered.

ANA testing: once during initial workup for symptomatic individuals; up to two additional tests per lifetime if new or more severe signs/symptoms develop.
ENA panel testing: covered when ANA is abnormal/raised and there is clinical correlation with a specific autoimmune disorder.
RF and anti‑CCP: once during initial workup for suspected RA; up to two additional lifetime tests if initial testing was nondiagnostic and symptoms persist or worsen.
Disease monitoring with ANA titers and routine ordering of proprietary multibiomarker panels for management or monitoring are not covered.

Note

Therapy selection guidance

Predictive biomarker assays (for example, PrismRA MSRC) may inform therapy selection by identifying patients unlikely to respond to specific agents (eg, TNF inhibitors). When considered, documentation should show how the prediction will influence therapeutic choices and that standard-of-care treatment decisions cannot be made without the assay result.

PrismRA has clinical validation data showing prediction of TNFi non‑response in CERTAIN and NETWORK‑004 cohorts; if used to guide therapy selection, include how a non‑response result would change the planned treatment (eg, choosing non‑TNFi biologic or JAK inhibitor).
Proprietary predictive tests used solely for therapy selection may still be reviewed for medical necessity and require clear documentation of clinical impact on treatment choice.

Note

Guideline stance on biomarker tests

Professional guidelines (ACR, NICE, RACGP and international task forces) do not currently endorse routine use of multibiomarker or proprietary index tests (eg, Vectra® DA, PrismRA, AVISE® panels) for primary diagnosis or routine disease management. Use of such tests should be reserved for scenarios where standard guideline‑recommended testing is inadequate and where the result will directly affect management.

ACR recommends HEp‑2 IF as the ANA gold standard and advises against ordering ANA subserologies without a positive ANA and clinical suspicion.
NICE and RACGP emphasize referral criteria and targeted testing (RF, anti‑CCP, CRP/ESR) for RA assessment; they do not recommend multibiomarker index tests for routine diagnosis.
When proprietary tests are ordered, provide evidence that the test will change management beyond existing guideline‑recommended assessments.

inv-48: MBDA / Vectra DA

DefinitionMBDA / Vectra DA: a 12-protein multi-biomarker panel (eg, IL-6, TNFRI, VCAM-1, CRP, SAA, leptin, resistin, MMPs, etc.) that generates a composite disease activity score for RA.

Correlation with clinical measuresMBDA score correlates with DAS28-CRP (r=0.72) and has been validated as a disease activity marker; may predict radiographic progression.

Utility and limitationsMay complement clinical assessment and influence treatment decisions in some studies, but responsiveness and routine management utility are mixed; not universally endorsed by guidelines.

inv-51: Proprietary autoimmune panels

DefinitionProprietary autoimmune panels: commercial test panels (eg, Avise Lupus, aiSLE DX, SLE-key) combining multiple analytes and algorithmic scoring to aid diagnosis or assess activity/risk in SLE and CTDs.

Examples and componentsExamples include AVISE Lupus (Avise®), which uses CB-CAPs and multiple autoantibodies, and aisle® DX and SLE-key which measure cytokines/mediators with algorithmic scores.

Policy stanceThese proprietary panels often report indexed algorithm scores and are specifically listed among tests that DO NOT MEET COVERAGE CRITERIA for diagnosis, prognosis, or monitoring in this policy.

inv-52: Multi-biomarker disease activity (MBDA) score / proprietary panels

DefinitionMulti-biomarker disease activity (MBDA) score / proprietary panels: laboratory panels that combine multiple biomarkers into an indexed score (eg, Vectra DA, PrismRA, AVISE CTD/SLE) intended to inform disease activity, prognosis, or therapeutic response.

Coding and examplesCPT/HCPCS codes associated with these proprietary panels include 81490 (Vectra DA), 0312U (Avise Lupus), 0447U/0521U (aisle® DX / Seronegative RA panel) among others.

Coverage summaryPolicy notes evidence for prognostic/predictive use in some studies (eg, PrismRA) but designates many proprietary panels as not meeting coverage criteria for routine diagnosis, prognosis, or monitoring of SLE/CTD and RA management.